Targeting cyclin-dependent kinases in anti-neoplastic therapy

Curr Opin Cell Biol. 2013 Dec;25(6):772-9. doi: 10.1016/j.ceb.2013.08.004. Epub 2013 Sep 6.

Abstract

Cell cycle progression is controlled by sequential activation of cyclin-dependent kinases (CDKs), which are often deregulated in cancer. Consequently numerous pharmacological inhibitors of CDKs have been developed with the aim of treating cancers. The article briefly reviews CDK inhibitors and their use to treat cancers, with specific focus on the use of biomarkers and drugs combination to improve their therapeutic efficacy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols
  • Biomarkers, Tumor / metabolism
  • Cyclin E / metabolism
  • Cyclin-Dependent Kinases / antagonists & inhibitors*
  • Cyclin-Dependent Kinases / metabolism
  • Humans
  • Myeloid Cell Leukemia Sequence 1 Protein / metabolism
  • Neoplasms / drug therapy*
  • Neoplasms / enzymology*
  • Neoplasms / pathology
  • Oncogene Protein p55(v-myc) / metabolism
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use*

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Cyclin E
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Oncogene Protein p55(v-myc)
  • Protein Kinase Inhibitors
  • Cyclin-Dependent Kinases